ImmPACT Bio Announces Opening of California-Based GMP Facility for Clinical Production of IMPT-314, a CD19/CD20 CAR T Therapy for B-Cell Malignancies and Autoimmune Diseases
/PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR)...